Cord blood immune cells tested against tough leukemia
NCT ID NCT04347616
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new treatment for adults with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment involved giving patients natural killer cells grown from donated umbilical cord blood, along with a drug called IL-2 to help those cells survive and work. Only 9 people took part before the study was stopped early, so we have limited information on how well it works or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
natural killer cells from umbilical cord blood, plus interleukin-2 (IL-2)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat acute myeloid leukemia who cannot have a stem cell transplant.
What could go wrong
This was a very early, small trial (only 9 people) that was terminated early, so results are limited. The treatment also carries risks like severe side effects or graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboud University Medical Center
Nijmegen, Netherlands